Enoxaparin thromboprophylaxis effective after hip replacement
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial GroupJ Bone Joint Surg Am. 2001 Mar;83-A(3):336-45
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
873 patients who had undergone elective total hip or knee replacement were randomized to receive 3 weeks of treatment with either enoxaparin or a placebo. This treatment was after subcutaneous injections of enoxaparin administered 7-10 days postoperatively to all patients. The primary outcome was the prevalence of venous thromboembolism or symptomatic pulmonary embolism during the treatment phase....
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue